Karex Berhad (5247) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Karex Berhad MYR 0.23, price MYR 0.44, upside -47.7%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Karex Berhad for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 0.3196 MYR – 1.05 MYR · fair‑value band 0.1600 MYR – 0.2300 MYR · the 0.4400 MYR price screens above the 0.2300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Karex Berhad in your weekly email
Every Wednesday you see whether Karex Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Karex Berhad, an investment holding company, manufactures and sells condoms in Malaysia. The company provides personal lubricants; probe covers; and catheters for transurethral drainage of the urinary bladder, as well as gloves. It also offers hand sanitizer and pre-vulcanised latex products.
Show more
Karex Berhad, an investment holding company, manufactures and sells condoms in Malaysia. The company provides personal lubricants; probe covers; and catheters for transurethral drainage of the urinary bladder, as well as gloves. It also offers hand sanitizer and pre-vulcanised latex products. In addition, the company engages in wholesale healthcare product related business. Karex Berhad operates in the Americas, Asia, Europe, and Africa. Karex Berhad serves brand owners, governments, non-governmental organizations, and retail purchasers. The company was founded in 1988 and is based in Port Klang, Malaysia.
Stock analysis
Karex Berhad (5247) currently trades at 0.4400 MYR, while our model-based Fair Value estimate is 0.2300 MYR, implying the stock looks roughly 91.3% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 0.3000 MYR per share, and 0 of the 9 models we run sit above the 0.4400 MYR price.
Bear case: the Earnings-Based group reads lowest at 0.0600 MYR, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.1600 MYR (bear) to 0.2300 MYR (bull), the price of 0.4400 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Karex Berhad reported revenue of 498M MYR in FY2025 versus 420M MYR in FY2021, a compound +4.4%/yr. Reported net income was 208K MYR in FY2025.
Key figures
Market cap 500M MYR (≈ $123M) · P/S ratio 1.04 · EPS (TTM) −0.0100 MYR · Dividend yield 2.3% · Net margin 0.0% · Return on equity −2.8% · Return on assets (EBIT) 1.9% · Operating margin −4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at −48%, 5247 screens richer than that median.
Fair Value models
Bear 0.1600 MYRFair Value 0.2300 MYRBull 0.2300 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +5.3% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−29.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.2%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−32% vs −44%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−48% · Bottom 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−3% · Bottom 25%
Operating margin (TTM)−5% · Bottom 25%
Growth and dividend
Revenue growth−22% · Bottom 25%
Dividend yield (TTM)2.3% · Below median
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B0.25× · Cheapest 25%
P/S (TTM)0.24× · Cheapest 25%
EV/EBITDA8.8× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 5
PAST (return on equity)0· sector 27
HEALTH (low debt)97· sector 98
DIVIDEND (yield)45· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Karex Berhad Fair Value". https://www.fairvalue-calculator.com/stock/5247
Frequently asked questions
Is Karex Berhad (5247) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.2300 MYR versus a price of 0.4400 MYR, about −48% upside (overvalued).
What is the fair value of 5247?
Our model-based fair value for Karex Berhad is 0.2300 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.4400 MYR.
What is the quality score of 5247?
Karex Berhad has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Karex Berhad (5247)?
Our model-based price target is the fair value of 0.2300 MYR (as of Sep 24, 2026) from 11 valuation models. Cautious scenario 0.1600 MYR, optimistic scenario 0.2300 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Karex Berhad stock forecast for 2026?
Our models put fair value at 0.2300 MYR, about −48% upside versus a price of 0.4400 MYR (overvalued). Cautious scenario 0.1600 MYR, optimistic scenario 0.2300 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Karex Berhad (5247)?
Karex Berhad reported trailing-twelve-month revenue of about 482M MYR (latest available figure, as of Sep 24, 2026).
Does Karex Berhad pay a dividend?
Karex Berhad currently shows a dividend yield of about 2.27% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Karex Berhad (5247)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Karex Berhad it is 0.2300 MYR per share (as of Sep 24, 2026), against a price of 0.4400 MYR. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Karex Berhad stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 5247 trades above its calculated fair value: price 0.4400 MYR, fair value 0.2300 MYR, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5247?
No. The price is what the market pays today (0.4400 MYR); the fair value is what the company's own numbers justify (0.2300 MYR). For Karex Berhad the two are 0.2100 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Karex Berhad worth?
The market values Karex Berhad at about 500M MYR (market capitalisation, as of Sep 24, 2026). Per share that is 0.4400 MYR; our models calculate a fair value of 0.2300 MYR per share.
What do the bullish and bearish scenarios say about 5247?
Our models span a range for Karex Berhad: cautious scenario 0.1600 MYR, base 0.2300 MYR, optimistic 0.2300 MYR per share (as of Sep 24, 2026, price 0.4400 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Karex Berhad (5247)?
Balance-sheet figures for Karex Berhad (as of Sep 24, 2026): return on equity −2.8%, debt of 0.07 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 5247 from its 52-week high?
Karex Berhad trades at 0.4400 MYR, about 56% below its 52-week high of 0.9931 MYR and 2% above the low of 0.4300 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2300 MYR is for.
Which stocks are comparable to Karex Berhad?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Karex Berhad stock attractive at the current price?
The data as of Sep 24, 2026: price 0.4400 MYR, calculated fair value 0.2300 MYR (−48%), Quality Score 43/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5247 calculated?
We run Karex Berhad through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2300 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Karex Berhad itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Karex Berhad (5247)?
The closing price on Sep 24, 2026 was 0.4400 MYR. Our model-based fair value is 0.2300 MYR, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Karex Berhad right now?
The price sits above even our optimistic bull case (0.2300 MYR). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Karex Berhad (5247) come from?
Earnings per share at Karex Berhad grew −17.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.5 %, EBIT margin −16.0 %, tax rate −1.3 %, residual (interest, one-offs) −4.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Karex Berhad
How large is the market capitalisation of Karex Berhad (5247)?
The market capitalisation of Karex Berhad is 500M MYR (≈ $123M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Karex Berhad (5247)?
The price-to-sales ratio of Karex Berhad is 1.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Karex Berhad (5247)?
Earnings per share at Karex Berhad are −0.0100 MYR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Karex Berhad (5247)?
The dividend yield of Karex Berhad is 2.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Karex Berhad (5247)?
The net margin of Karex Berhad is 0.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Karex Berhad (5247)?
The return on equity (ROE) of Karex Berhad is −2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Karex Berhad (5247)?
On an EBIT basis the return on assets of Karex Berhad is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Karex Berhad (5247)?
The operating margin of Karex Berhad is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Karex Berhad (5247)?
Revenue at Karex Berhad is growing −22.2% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Karex Berhad (5247)?
Earnings per share at Karex Berhad are growing +236% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Karex Berhad (5247) generate?
The free cash flow of Karex Berhad is −21.0M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Karex Berhad (5247) carry?
The net debt of Karex Berhad is 178M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Karex Berhad in the live analysis
One click puts Karex Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
